HOSPITAL UNIVERSITARIO RUBER

2019

1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

   Frontiers in Oncology, Vol. 9, Núm. APR

2. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

   Future Oncology, Vol. 15, Núm. 19, pp. 2211-2225

3. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

   Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

4. Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia

   JAMA Dermatology, Vol. 155, Núm. 6, pp. 724-728

5. Breast cancer

   Nature Reviews Disease Primers, Vol. 5, Núm. 1

6. Churg-Strauss syndrome and pregnancy. Case report and bibliographic review.

   Ginecologia y Obstetricia de Mexico, Vol. 87, Núm. 11, pp. 756-761

7. Clinical implications of extracellular HMGA1 in breast cancer

   International Journal of Molecular Sciences, Vol. 20, Núm. 23

8. Effect of Early Metoprolol During ST-Segment Elevation Myocardial Infarction on Left Ventricular Strain: Feature-Tracking Cardiovascular Magnetic Resonance Substudy From the METOCARD-CNIC Trial

   JACC: Cardiovascular Imaging, Vol. 12, Núm. 7, pp. 1188-1198

9. Efficacy of PI3K inhibitors in advanced breast cancer

   Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, Núm. 10, pp. x12-x20

10. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials

    Oncologist, Vol. 24, Núm. 8, pp. 1041-1047

11. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial

    JAMA Oncology, Vol. 5, Núm. 11, pp. 1556-1563

12. Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    Annals of Oncology, Vol. 30, Núm. 3, pp. 365-373

13. Hair disorders in cancer survivors

    Journal of the American Academy of Dermatology, Vol. 80, Núm. 5, pp. 1199-1213

14. Hair disorders in patients with cancer

    Journal of the American Academy of Dermatology, Vol. 80, Núm. 5, pp. 1179-1196

15. Hydrodynamic and electrophoretic properties of trastuzumab/HER2 extracellular domain complexes as revealed by experimental techniques and computational simulations

    International Journal of Molecular Sciences, Vol. 20, Núm. 5

16. IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

    Future Oncology, Vol. 15, Núm. 17, pp. 1951-1961

17. Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm

    Current Breast Cancer Reports, Vol. 11, Núm. 4, pp. 248-258

18. In-vivo assessment of a case of cutaneous sarcoidosis using reflectance confocal microscopy

    Anais Brasileiros de Dermatologia, Vol. 94, Núm. 1, pp. 93-95

19. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

20. NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

    Breast Cancer Research, Vol. 21, Núm. 1